1
Clinical Trials associated with Human Fcγ1-Fel d1 fusion protein(NIAID)A Dose-Escalating Phase 0 Study to Evaluate the Safety and Local Cutaneous Reactivity of Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD) in Cat-allergic Healthy Volunteers
The purpose of this trial is to show that Intradermal Human Fcγ1-Fel d1 fusion protein (GFD) is able to block the skin reaction to cat allergen in cat allergic subjects compared to the skin reaction to cat allergen alone. This research project is also testing the safety and tolerability of this new, experimental treatment, compared to the current treatment of cat allergen alone.
100 Clinical Results associated with Human Fcγ1-Fel d1 fusion protein(NIAID)
100 Translational Medicine associated with Human Fcγ1-Fel d1 fusion protein(NIAID)
100 Patents (Medical) associated with Human Fcγ1-Fel d1 fusion protein(NIAID)
100 Deals associated with Human Fcγ1-Fel d1 fusion protein(NIAID)